Association between plasma angiotensinogen level and response to valsartan among sample of Iraqi hypertensive patients

Wiad Lek. 2024;77(9):1662-1671. doi: 10.36740/WLek/191331.

Abstract

Objective: Aim: The main aim of the present paper is to investigate allele frequencies of rs1799983 polymorphism eNOS genes and to determine association between rs1799983 polymorphism of eNOS gene and essential hypertension in Iraqi hypertensive patients.

Patients and methods: Materials and Methods: Data obtained at the Al-Diwaniyah teaching hospital in Iraq by researchers from the Department of Pharmacology and Therapeutics in the College of Medicine at University of Al-Qadisiyah from July 2022 to July 2023. All participants (aged 20 to 70) had been taking valsartan 160 mg once day for essential hypertension for at least two weeks before to the study. There were a total of 90 participants, 37 males and 53 women. Initial investigations of hypertension have indicated that the angiotensinogen gene has a substantial impact in susceptibility to essential hypertension through observational cross sectional descriptive single center study.

Results: Results: Indicate, in patients with essential hypertension, that the "AGT gene A>G (rs699) and C>T(rs5051)" have high angiotensinogen level, and there is no signif i cant association between these two (rs699, rs5051) and responsiveness to valsartan (P >0.05).

Conclusion: Conclusions: Result showed the most common allele for rs699 was G allele (67%) while the most frequent genotype was AG (49%) and regarding rs5051 the most frequent allele was C (54%) while the most frequent genotype was CT (46%). In this study we demonstrate the lack of signif i cant association between two these polymorphisms and clinical response to valsartan (P >0.05).

Keywords: AGT Gen; Iraq; essential hypertension; polymorphism; valsartan.

MeSH terms

  • Adult
  • Aged
  • Angiotensinogen* / blood
  • Angiotensinogen* / genetics
  • Antihypertensive Agents* / therapeutic use
  • Cross-Sectional Studies
  • Essential Hypertension / blood
  • Essential Hypertension / drug therapy
  • Essential Hypertension / genetics
  • Female
  • Gene Frequency
  • Humans
  • Hypertension* / drug therapy
  • Hypertension* / genetics
  • Iraq
  • Male
  • Middle Aged
  • Nitric Oxide Synthase Type III / genetics
  • Polymorphism, Single Nucleotide
  • Valsartan* / therapeutic use
  • Young Adult

Substances

  • Valsartan
  • Angiotensinogen
  • Antihypertensive Agents
  • Nitric Oxide Synthase Type III